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Abstract
Background: In 1993, the Performance Scales© was created to assess multi-dimensional disability in multiple
sclerosis (MS). This tool has been used in a variety of settings and study designs internationally. The present work
provides an overview of the history and psychometric characteristics of the Performance Scales©, reviews its use
over the past two decades, and summarizes its responsiveness to subgroup differences.
Methods: A Google Scholar and Ovid search yielded 230 articles citing the Performance Scales©, of which 82
studies used the tool in empirical research. Twelve articles provided sufficient information to enable computation of
effect sizes. Forest plots were used to show effect sizes for the overall summary score and by domain by patient
demographics, MS disease trajectory, and treatment adherence.
Results: The Performance Scales© evidenced sensitivity to clinically important differences by disease trajectory and
age (for selected domains). In contrast, groups distinguished by patient adherence to disease-modifying therapies
and ethnicity were relatively small.
Conclusions: The Performance Scales© has been used in a large number of studies since its development,
suggesting that this psychometrically sound tool is acknowledged to be a useful tool for MS clinical research. It is
recommended that future work include the entire measure, so that the whole-person impact of MS can be
characterized and considered in MS outcome research.
Keywords: Patient-reported outcomes, Multiple sclerosis, Disability, Quality of life, Clinical trials outcomes,
Rehabilitation, Epidemiological research, Performance Scales, Review, Responsiveness, Interpretation
Background
The use of patient-reported outcomes has become in-
creasingly standard in multiple sclerosis (MS) clinical re-
search and practice. While clinical exams can provide
useful information about objective disability indicators
(e.g., mobility difficulties), it is widely acknowledged that
important aspects of treatment impact can only be
addressed by asking the patient directly. For example,
fatigue, numbness, and cognitive difficulties can im-
pact an individual’s ability to engage in work and
other important activities of daily living and they are
not always visible to the ‘objective’ observer. In 1993,
the Performance Scales© was created to assess multi-
dimensional disability in MS. This tool has been used
in a variety of settings and study designs internation-
ally. Yet, recent reviews of MS outcome measures
have neglected to mentioned or cite this measure
[1, 2], despite its use in a substantial number of re-
search studies. Its brevity, strong psychometric char-
acteristics, and availability in many language translations
render it useful in a number of clinical and research
contexts. The present work provides an overview of
the history and psychometric characteristics of the
Performance Scales©, reviews its use over the past two
decades, and summarizes its responsiveness to subgroup
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History of the Performance Scales©
The development of the Performance Scales© was moti-
vated by the need to have patient-reported indices of
disability to provide assessment alternatives to the
neurologic examination. The gold standard for assessing
disability in MS is the Expanded Disability Status Scale
(EDSS) [3], which is scored on the basis of clinician an-
swers to the Functional Systems Scores (FSS) and re-
quires substantial clinician time (about 40 min). The
EDSS score is driven by ambulation disability and does
not reflect other, important but hidden (i.e., not visible)
aspects of disability sufficiently (e.g., cognitive symptoms).
Additionally, the EDSS has well-documented issues with
inter-rater reliability in the minimal-to-moderate range of
disability. This means that two neurologists rating the
same individual may vary in their scoring by one point on
the ten-point scale [4, 5]. This one-point difference is the
same as the standard definition of clinically significant
change used in clinical trials [6]. Furthermore, the EDSS is
differentially sensitive to change, depending on the initial
disability level. Accordingly, a change of 1 point on the
EDSS reflects more dramatic change at higher levels of
disability. This reliability problem reduces the responsive-
ness of the EDSS as well as the statistical power of any
study that uses the EDSS as an outcome.
In addition to the above psychometric concern of reli-
ability, the Performance Scales© measure was created to
consider more relevant domains of MS-specific disabil-
ity. This focus on content validity was stimulated by
qualitative research with MS patients in the context of
developing a psychosocial intervention for patients and
caregivers [7]. Elicited patient description of their dis-
ability and its impact on their life did not correspond to
their healthcare providers’ descriptions of their disability
[8]. The patients’ answers reflected a wide range of do-
mains that were not reflected by the EDSS or FSS, or by
generic health status measures, such as the widely used
SF-36™. Hence it was clear that there was a need for a
robust measure of MS disability that covered the full
multi-dimensional territory affected.
Psychometric characteristics of the Performance
Scales©
Domains
The Performance Scales© includes the following eight
domains: Mobility, Hand Function, Vision, Fatigue,
Cognitive, Bladder/Bowel, Sensory, and Spasticity
Symptoms.
Format and response options
Each domain scale begins with a brief definition of the
domain, and then asks the respondent to endorse what
level of disability s/he experiences with regard to per-
forming his/her normal activities of daily living. The
estimated completion time of 2 min. Higher scores rep-
resent more impairment.
Validation studies of the Performance Scales©
The initial validation of the Performance Scales© was a
multi-site, cross sectional study implemented with 13
MS centers around the United States and Canada that
was completed in 1997 [9]. The Schwartz et al. [9] study
included 274 MS patients and 296 healthy controls [9].
The study evaluated the reliability and validity of the
Performance Scales© in comparison to clinical measures,
and other patient-reported outcomes. Subsequent work
by Marrie and Goldman [10] evaluated the Performance
Scales© criterion and construct validity in 44 people
with MS, and work by Motl and Snook [11] evaluated its




The test-retest reliability coefficient for the total score of
the Performance Scales© was 0.89, and the coefficients
for the eight domain scores ranged from 0.65 to 0.91.
The Mobility domain score had the highest test-retest
reliability, and the Sensory domain score had the lowest
test-retest reliability.
Internal consistency
Because each domain score has only one score, the in-
ternal consistency of the Performance Scales© domain
scores was not evaluated. The alpha reliability of the




The Performance Scales© summary score is associated
in the expected direction with other clinical and self-
reported measures of disability. Using Cohen’s [12]
criteria for small (r = 0.1), medium (r = 0.3), and large
(r = 0.5) correlation coefficients, we found that the
Performance Scales© summary score had a small correl-
ation with disease duration, and large correlations
with the disease-specific and generic measures of
functional status. Motl and colleagues confirmed large
correlations with disease-specific measures, reported
moderate correlations with the performance-based ac-
celerometer [13], and small correlations with self-
reported exercise.
Discriminant validity
In our original validation study, we found that the
Performance Scales© summary score is able to distin-
guish the following known groups: healthy control
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subjects; minimally, moderately, and severely disabled
MS patients [9]. Remarkably similar mean values by level
of EDSS disability were reported in an independent rep-
lication study by Motl and colleagues [14]. Unlike the
generic functional health measures included in the study,
the Performance Scales© means were in the expected
order (i.e., lowest to highest), whereas the generic health
measures yielded an incorrect order with respect to the
EDSS groupings. This finding is consistent with past re-
search that has documented that disease-targeted scales
provide unique information not captured by generic
measures [15], and thus may be more sensitive to higher
levels of disability.
Incremental validity of the Performance Scales
The Performance Scales© tool assesses self-reported
disability. Its overlap with the Symptom Inventory
(SI) measure of impairment is relatively high among
minimally and moderately disabled people with MS
(r = 0.80) but substantially lower among severely dis-
abled people with MS (r = 0.60 for the SI long form,
and 0.48 for the SI short form). This finding suggests
that the two measures might have more incremental
validity among severely disabled patients. Of note,
the Performance Scales© summary scores explained
41% of the variance in predicting utility scores; 38%
of the variance in predicting the clinician-rated EDSS;
36% of the variance in predicting the clinician-rated
Disease Steps; and 30% of the variance in predicting the
clinician-rated Ambulation Index. Motl and colleagues
replicated these same incremental validity analyses in an
independent sample of 129 MS patients [14]. These ana-
lyses suggest that the Performance Scales© summary score
measures an outcome that is distinct and complementary
to existing clinical, MS-specific, and generic self-report
measures.
Scoring and alternative uses of the Performance
Scales©
The standard scoring algorithm for the Performance
Scales© is a simple ordinal summary index. Factor
analyses support its unidimensionality, and confirm a
very high correlation between a simple sum and a
weighted sum based on factor loadings [16]. It is also
possible to use the individual domain scores to de-
scribe change over time. This use of the Performance
Scales© has been tested and validated in a number of
studies using MS patient registry data [10]. This ap-
proach may be useful in a clinical setting to identify
areas of focus for clinical intervention. The caveat to
this use of individual domain scores is that it may
lead to ignoring the multidimensional causes of dis-
ability in MS, and thus render the scores less respon-
sive and relevant.
Available translations of the Performance Scales©
There are currently 20 translations of the Performance
Scales©, created using the standard methods recom-
mended by large clinical trial collaborative groups and
other organizations actively involved in culturally-
equivalent translations of patient-reported outcomes
[17–20]. The availability of so many translations makes
this patient-reported outcome tool particularly feasible
for international collaborations.
The present work sought to investigate how the
Performance Scales© has been used since its inception,
and to estimate the tool’s responsiveness to clinically im-
portant change.
Methods
A Google Scholar search was done searching all pub-
lished articles referencing the Schwartz et al. [9] and
Marrie and Goldman [10] articles through June 3, 2016,
since these two articles were the most direct validation
studies of the tool. Additionally an Ovid search was
done using Medline only and the term “Performance
Scales”. It was followed by a second search using all
Ovid databases and the terms “Performance Scales” and
“multiple sclerosis.” Both authors then reviewed each
article according to the following inclusion and exclu-
sion criteria. Articles were included for further consider-
ation if they actually used the Performance Scales© in
the reported study. Articles were excluded if they were a
review, book, or thesis; did not use the Performance
Scales© in the reported study; were not in English; were
a copyright infringement; or we were not able to procure
a copy of the article despite multiple efforts. From those
citations that presented empirical data, we identified the
papers that provided means for patient subgroups or
study groups. This information was then used to cal-
culate an effect size using Cohen’s D [12] as follows:
d ¼ M1− M2SDpooled for means with independent samples. For-
est plots showing the effect sizes were generated to
show effect size by patient demographics, MS disease
trajectory, and treatment adherence.
All analyses were done using Microsoft Office Excel
2010 and Stata 13 [21].
Results
Figure 1 shows the exclusion tree for articles that
were identified in the Google Scholar and both Ovid
searches. After removing duplicate articles as well as
articles that were not referring to the Performance
Scales© (many articles used “performance scales” as a
general term), 230 citations remained, Of the 230 ci-
tations, 148 were excluded because they were not em-
pirical studies, referred to a different tool used and/or
validated in the original Schwartz et al. [20] study,
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did not use the Performance Scales©, were not in
English, or were a copyright infringement. From this
subset of 82 articles that did use the Performance
Scales©, only 12 articles provided sufficient informa-
tion to enable computation of effect sizes.
Table 1 and the Appendix provide further information
about the 82 studies using the Performance Scales© on
over 321,000 people with MS.1 About 73% of the stud-
ies were observational, 21% were measurement valid-
ation, and 6% were intervention studies. The majority
of studies used cross-sectional designs, and about one
third were longitudinal. Of the longitudinal studies,
only one included more than two timepoints. About
half of the studies utilized data from the North
American Research Committee on MS (NARCOMS)
registry, and the remaining studies used data from
the Veterans Health Administration, local chapters of
the National MS Society, and MS clinics based at
hospitals or universities. Funding sources for the
studies were dominated by foundation funding,
followed by federal grants, industry grants, and un-
specified or internal funding.
Of the 82 articles that used the Performance Scales©,
52 used the measure as an outcome, and 30 used it ei-
ther as a predictor or to classify their sample. The ma-
jority of studies used the measure to define disability
status or used it as a general health outcome. While the
majority of studies used the full measure, there were a
number that used either one or some of the domain
scores. In total, 47 studies used all 8 of the Performance
Scales© domain scores, 21 studies used only one domain
score, and 14 used between 2 and 7 domain scores. The
most commonly used domain score was the Mobility do-
main score which was used in 67 studies, followed by
Fatigue which was used in 60 studies. Figure 2 shows the
number of studies that used each of the 8 domain
scores.
Figures 3a-l show the effect sizes with 95% confidence
interval bars by subgrouping variable and domain, as
available. In comparisons of adherent versus non-
adherent patients, the Performance Scales© Summary
Score detected a small effect size difference, whereas the
Mobility and Fatigue effect size differences were moder-
ate (i.e., clinically significant). In comparisons by disease
trajectory, small effect size differences were detected by
the Mobility and Cognitive domains; moderate effect
size differences were detected by the Bladder/Bowel,
Hand Function, Sensory, and Vision domains; and large
effect size differences were detected by the Fatigue and
Spasticity domains. Effect sizes varied, however, for each
domain score by specific comparison. In ethnicity com-
parisons, detected effect size differences were small
Fig. 1 Exclusion tree for articles that were identified in the Ovid search
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across all domain scores. In comparisons by age group
(<=30 years versus > 30), effect size differences were
small for Cognitive, Depression, Mobility, and Tremor/
Coordination; but moderate for Fatigue and Bladder/
Bowel.
Discussion
The Performance Scales© has been used in a large num-
ber of studies since its development, suggesting that this
psychometrically sound tool is acknowledged to be a
useful and reliable tool for MS clinical research. Our re-
sults support the tool’s sensitivity to clinically important
differences by disease trajectory and age (for selected
domains). Based on Cohen’s effect size interpretation
guidelines [12], the Performance Scales© Summary score
is able to detect small differences between groups, and
thus could be used in studies comparing the effective-
ness of disease-modifying therapies for MS. The individ-
ual domain scores demonstrated sensitivity to small,
moderate, and large group differences; depending on the
study research question and comparison group. We
would thus recommend collecting all eight domain
scores to maximize the likelihood of detecting small dif-
ferences, and being able to characterize the domain most
effected by having data on all the individual domain
scores. In contrast, groups distinguished by patient ad-
herence to disease-modifying therapies and ethnicity
were relatively small.
The multidimensional format of the Performance
Scales© can be particularly useful for MS outcomes
research because it allows clinical researchers to
characterize the profile of changes within and across in-
dividuals. Illustrated by the range of effect sizes detected
across domains and by grouping variable, our review
provides useful information for planning future studies.
For example, if an investigator wishes to design a study
with sufficient power to compare disability levels across
groups as a function of treatment adherence, then the
sample sizes will need to be on the order of about 300
per group [8]. This will enable adequate statistical power
Fig. 2 Bar chart showing how often each of the Performance Scales© domain scores were used throughout the reviewed studies






Study Type n % n %
Observational 60 73% 11 92%
Intervention 5 6% 1 8%
Measurement Validation 17 21% 0 0%
Design Type
Cross Sectional 51 62% 6 50%
Longitudinal 29 35% 6 50%
Randomized Controlled Trial 2 2% 0 0%
Participant Source
NARCOMS 43 52% 7 58%
Vetrans Health Administration 10 12% 1 8%
Midwest Chapters, National MS Society 5 6% 0 0%
Cleveland Clinic Mellen Center 9 11% 2 17%
Other 15 18% 2 17%
Funding Sourcea
Internal/Academic 8 10% 2 17%
Industry 21 26% 4 33%
Federal 25 30% 2 17%
Foundation 51 62% 8 67%
Not Specified 11 13% 0 0%
aStudies may have more than 1 funding source
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given a Type I error rate of 0.05 . In contrast, if dis-
ease trajectory or age-related differences are the pri-
mary focus, then the study can include only about 62
patients per group to have similar power and Type I
error rate. Thus, the comparisons shown in the
Forest Plots included herein can assist investigators
in planning future studies using the Performance
Scales©.
The limitations of this work include the fact that rela-
tively few of the published empirical studies provided
data that allowed for their inclusion in the effect size
computations. We are thus only able to comment on
the tool’s responsiveness in a small subsample of the lit-
erature. Further, information on sex and age distribu-
tions was limited. Future research might address how
sex and age distributions differ in studies using the Per-
formance Scales© or other disease-specific patient-
reported outcomes.
It is unfortunate that so few studies used and/or re-
ported the Performance Scales© Summary Score. Of the
82 studies, 35 are using only one or some of the domain
scores, rather than the whole multidimensional measure
as it was intended. It is recommended that future work
include the entire measure, so that the whole-person im-
pact of MS can be characterized and considered in MS
outcome research.
Conclusion
The Performance Scales© has been used in a large
number of studies since its development. The tool is
sensitive to small changes over time in overall MS
disability, and to moderate and small changes over time
in selected domains. This responsiveness to clinically
relevant change as well as its well-documented strong
psychometric characteristics make it a useful tool for
MS clinical research. lt is recommended that future
work include the entire measure, so that the whole-
person impact of MS can be characterized and consid-
ered in MS outcome research.
Endnote
1Since many studies use NARCOMS samples or sub-
samples, it is not possible to know how many of the
321,000 people are actually the same person in multiple
studies. Data bases provided to NARCOMS investigators
are de-identified.
Appendix
Studies utilizing the Performance Scales© 1999–2015.
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